ALSO NOTED: Erbitux surge doesn't produce ImClone profit; Glenmark to sell MeyerZall drugs in S. Africa;

> Despite rising Erbitux sales, ImClone Systems lost $916,000 in the third quarter; the culprit was higher operating costs, including a $50 million charge for a patent lawsuit settlement. Report

> Indian drug maker Glenmark Pharmaceuticals has inked a deal with South Africa-based MeyerZall Laboratories to market a handful of topical dermatology drugs in that country. Report

> Celgene almost doubled its profits in the third quarter, to $38.8 million from $20.4 million the same period last year; revenues were up by $104 million to $349.9 million. Report

> Belgium-based Galapagos shares shot up 12 percent on news that the company has inked a massive deal with Jassen Pharmaceutica, a division of Johnson & Johnson. Report

> The FDA has issued an approvable letter for Noven Pharmaceutical's Stavzor, a treatment for manic episodes associated with bipolar disorder, an adjunctive therapy in multiple seizure types, and prophylaxis of migraine headaches. Report

And Finally... One way to help wipe out scary drug-resistant staph? Screen patients as they enter the hospital. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.